Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H12O6 |
| Molecular Weight | 180.1561 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO
InChI
InChIKey=BJHIKXHVCXFQLS-PQLUHFTBSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5+,6-/m1/s1
| Molecular Formula | C6H12O6 |
| Molecular Weight | 180.1561 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tagatose is a functional sweetener. It is naturally occurring and often found in dairy products. Tagatose is similar in texture and sweetness to sucrose (table sugar) but with only 38% of the calories. It is approved for use as a food additive as a low-calorie sweetener. Only 15 - 20 % of Tagatose is absorbed in the small intestines and metabolized similarly to sucrose; the bulk of ingested tagatose is fermented in the colon by bacteria producing short chain fatty acids which are subsequently absorbed and metabolized by the body without affecting insulin levels. Tagatose is being investigated by Spherix for the treatment of obesity and type II diabetes. Tagatose consumed orally significantly blunts the rise in plasma glucose seen after oral glucose in patients with diabetes mellitus in a dose-dependent manner without significantly affecting insulin levels. It has been suggested that Tagatose may act by attenuating the absorption of glucose in the intestines.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00955747
Patients with type II diabetes were instructed to consume 15 grams of tagatose dissolved in water every day for one year.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25899632
A clinically isolated strain of Streptococcus mutans GS5 was grown in TY medium at 37 deg-C for 24 hours. After 24 hours the culture was diluted to OD600 = 0.3 and inoculated into a solution of 10% w/v Tagatose in TY medium (with and without 1% w/v sucrose). The inoculated tagatose solution was incubated at 37 deg C and OD600 measured at 4, 8, 12, and 20 hours. The pH of the inoculated solution was measured at 12 hours. d-tagatose significantly inhibited the acid production and water-insoluble glucan synthesis of GS5 in the presence of 1% sucrose, and the inhibitory effect of acid production by D-tagatose was significantly stronger that of xylitol in presence of sucrose.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:52 GMT 2025
by
admin
on
Mon Mar 31 17:50:52 GMT 2025
|
| Record UNII |
T7A20Y888Y
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
459614
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Tagatose
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
47693
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
4249
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
78
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
1642904
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
m10431
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID3047897
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
977
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
C030192
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
92092
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
T7A20Y888Y
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
SUB26542
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
16443
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
41847-61-4
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
ALTERNATIVE | |||
|
SUB129913
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
201-772-3
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
41847-01-2
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
ALTERNATIVE | |||
|
100000091290
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
DB04936
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
87-81-0
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY | |||
|
352
Created by
admin on Mon Mar 31 17:50:52 GMT 2025 , Edited by admin on Mon Mar 31 17:50:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> ACTIVATOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |